In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma's Reputation In A Post-Fact World

Executive Summary

How should an industry built on expertise, evidence and facts adapt to a new, break-the-wheel era that’s had enough of the experts? Four points to act on before the Tweetstorm visits the C-suite.

You may also be interested in...



The New World Of Pharma – Markets, Messaging And The Flash Mob

Our look back at 2016 and at prospects for the year ahead plots a rush of often conflicting head and tail winds, all requiring unrelenting focus from the C-suite on what matters to preserving pharma's vital public license to operate. Events in the sales-leading US market remain the key driver of change and a test ground for managing the competitive and reputational challenges industry faces from a more restive – and powerful – customer base.

Pharma's Latest Davos Pledge: Sincere, Or Just Keeping Up Appearances?

Many hope the "dialogue of the deaf" between pharma and other healthcare stakeholders can be truly bridged by the industry's latest Davos declaration to collaborate in targeting chronic diseases of the poor.

Lilly's Bridge Builder, From Indiana To South Africa

Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV005009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel